New Alzheimer’s Trial Data; Microbiome and MS; Monkeypox’s Neuro Complications

The oral beta-amyloid blocker ALZ-801 (valiltramiprosate) reduced plasma phosphorylated tau (p-tau181) by 41% and preserved hippocampal volume in a phase II study of Alzheimer’s patients with an APOE4 allele, Alzheon announced.

Investigational crenezumab did not reduce clinical decline or change disease-relevant biomarkers in two phase III trials of people with early Alzheimer’s. (JAMA Neurology)

With recent developments in Alzheimer’s research, scientists at drug firms around the world are optimistic for a breakthrough. (The Sunday Times)

Six metabolites, including four that were sugar-related, were associated with lower global cognitive function in people of diverse races and ethnicities. (Alzheimer’s & Dementia)

The gut microbiome was linked with multiple sclerosis (MS) risk and disease course. (Cell)

A second expanded-access patient with secondary progressive MS showed continued clinical improvements after 6 months of treatment with intranasal foralumab, Tiziana Life Sciences said.

Combining a seed amplification assay with an enzyme-linked immunosorbent assay (ELISA) for alpha-synuclein aggregates provided better information about Parkinson’s disease severity. (Neurology)

A single infusion of adjunctive rituximab led to better 4-month outcomes in new-onset generalized myasthenia gravis, the RINOMAX trial showed. (JAMA Neurology)

A molecular circadian clock may help brains recover after injury. (eNeuro)

Headaches, mood disturbances, and rare presentations of encephalitis, transverse myelitis, and seizures have been associated with monkeypox virus. (JAMA Neurology)

Healthy lifestyle factors were linked with a significantly lower risk of dementia in people with type 2 diabetes. (Neurology)